{
    "meta": {
        "portal_name": "pharmacokinetics",
        "language": "en",
        "updated": "20150503"
    },
    "schema": {
        "html:portal": "http://en.recuweb.com/pharmacokinetics/",
        "graph:videos": "http://en.recuweb.com/graph/v1.0/pharmacokinetics/pharmacokinetics/videos.json",
        "graph:news": "http://en.recuweb.com/graph/v1.0/pharmacokinetics/pharmacokinetics/news.json",
        "graph:blogs": "http://en.recuweb.com/graph/v1.0/pharmacokinetics/pharmacokinetics/blogs.json"
    },
    "items": {
        "seekingalpha.com/2015/05/momenta-pharmaceuticals-mnta-ceo-craig-wheeler-on-q1-2015-results-seeking": {
            "title": "Momenta Pharmaceuticals'(MNTA) CEO Craig Wheeler on Q1 2015 Results... - Seeking Alpha...",
            "snippet": "Momenta Pharmaceuticals'(MNTA) CEO Craig Wheeler on Q1 2015 Results...Seeking AlphaRandomized, double-blind, single-dose study in healthy volunteers to compare the pharmacokinetics, safety, tolerability, and immunogenicity of M923, versus EU source...",
            "date": "2015-05-02",
            "categories": "pharmacokinetics",
            "tags": "immunogenicity,study,healthy,pharmaceuticals,results,double,blind,pharmacokinetics,safety,tolerability",
            "recuweb_url": "http://en.recuweb.com/pharmacokinetics/seekingalpha.com/2015/05/momenta-pharmaceuticals-mnta-ceo-craig-wheeler-on-q1-2015-results-seeking",
            "resource_url": "http://news.google.com/?hl=en&q=pharmacokinetics&output=atom&nord=1",
            "source_url": "http://seekingalpha.com/article/3129996-momenta-pharmaceuticals-mnta-ceo-craig-wheeler-on-q1-2015-results-earnings-call-transcript"
        },
        "money.cnn.com/2015/05/cytrx-reports-first-quarter-2015-financial-results": {
            "title": "CytRx Reports First Quarter 2015 Financial Results...",
            "snippet": "a Phase 1b clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors and a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors. CytRx plans to expand its pipeline of...",
            "date": "2015-05-01",
            "categories": "tumor,pharmacokinetics",
            "tags": "trial,patients,results,phase,clinical,pharmacokinetics",
            "recuweb_url": "http://en.recuweb.com/pharmacokinetics/money.cnn.com/2015/05/cytrx-reports-first-quarter-2015-financial-results",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacokinetics&format=RSS&cc=us",
            "source_url": "http://money.cnn.com/news/newsfeeds/articles/prnewswire/LA95923.htm"
        },
        "generalsurgerynews.com/2015/05/fda-approves-ixinity-a-recombinant-factor-ix-general-surgery-news": {
            "title": "FDA Approves Ixinity, a Recombinant Factor IX - General Surgery News...",
            "snippet": "General Surgery NewsFDA Approves Ixinity, a Recombinant Factor IXGeneral Surgery NewsApproval was based on a Phase I/III, open-label, uncontrolled, multicenter, global study evaluating safety, efficacy and pharmacokinetics in previously treated...",
            "date": "2015-05-01",
            "categories": "surgery,pharmacokinetics",
            "tags": "efficacy,study,safety,general,fda,phase,pharmacokinetics",
            "recuweb_url": "http://en.recuweb.com/pharmacokinetics/generalsurgerynews.com/2015/05/fda-approves-ixinity-a-recombinant-factor-ix-general-surgery-news",
            "resource_url": "http://news.google.com/?hl=en&q=pharmacokinetics&output=atom&nord=1",
            "source_url": "http://generalsurgerynews.com/ViewArticle.aspx?d=Web+Exclusives&d_id=243&i=May+2015&i_id=1184&a_id=32321"
        },
        "brazilbusiness.einnews.com/2015/04/johnson-&-discuss-adme-in-preclinical-and-clinical-studies-to-guide": {
            "title": "Johnson & Johnson discuss ADME in preclinical and clinical studies to guide and accelerate clinical...",
            "snippet": "Renowned industry expert Mario Monshouwer, Senior Director Drug Metabolism Pharmacokinetics & Bioanalysis at Johnson & Johnson will be presenting on: Exploratory ADME in preclinical and clinical studies to guide and accelerate clinical development...",
            "date": "2015-04-30",
            "categories": "metabolism,pharmacokinetics",
            "tags": "drug,metabolism,pharmacokinetics,mario,studies,clinical,development",
            "recuweb_url": "http://en.recuweb.com/pharmacokinetics/brazilbusiness.einnews.com/2015/04/johnson-&-discuss-adme-in-preclinical-and-clinical-studies-to-guide",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacokinetics&format=RSS&cc=us",
            "source_url": "http://brazilbusiness.einnews.com/pr_news/262894814/johnson-johnson-discuss-adme-in-preclinical-and-clinical-studies-to-guide-and-accelerate-clinical-development"
        },
        "streetinsider.com/2015/04/retrophin-rtrx-receiives-fda-clearance-to-commence-re-024-studies": {
            "title": "Retrophin (RTRX) Receiives FDA Clearance to Commence RE-024 Studies -...",
            "snippet": "Retrophin (RTRX) Receiives FDA Clearance to Commence RE-024 Company is initiating a Phase 1 trial in healthy adult subjects to evaluate safety, tolerability, and pharmacokinetics, with enrollment expected to begin in the coming weeks. RE-024 is...",
            "date": "2015-04-30",
            "categories": "pharmacokinetics",
            "tags": "enrollment,enrollment-expected,expected,expected-to-begin,begin,coming,coming-weeks,weeks,trial,trial-in-healthy,healthy,healthy-adult,healthy-adult-subjects,adult,adult-subjects,subjects,subjects-to-evaluate,evaluate,evaluate-safety,safety,initiating,fda,clearance,retrophin,studies,company,phase,tolerability,pharmacokinetics",
            "recuweb_url": "http://en.recuweb.com/pharmacokinetics/streetinsider.com/2015/04/retrophin-rtrx-receiives-fda-clearance-to-commence-re-024-studies",
            "resource_url": "http://news.google.com/?hl=en&q=pharmacokinetics&output=atom&nord=1",
            "source_url": "http://streetinsider.com/Corporate+News/Retrophin+(RTRX)+Receiives+FDA+Clearance+to+Commence+RE-024+Studies/10509359.html"
        },
        "businesswire.com/2015/04/retrophin-announces-fda-review-of-ind-for-re-024-and-clearance": {
            "title": "Retrophin Announces FDA Review of IND for RE-024 and Clearance to Proceed With Phase 1 Clinical...",
            "snippet": "The Company is initiating a Phase 1 trial in healthy adult subjects to evaluate safety, tolerability, and pharmacokinetics, with enrollment expected to begin in the coming weeks. RE-024 is being developed for the treatment of pantothenate...",
            "date": "2015-04-30",
            "categories": "pharmacokinetics",
            "tags": "treatment,enrollment,enrollment-expected,expected,expected-to-begin,begin,coming,coming-weeks,weeks,trial,trial-in-healthy,healthy,healthy-adult,healthy-adult-subjects,adult,adult-subjects,subjects,subjects-to-evaluate,evaluate,evaluate-safety,safety,initiating,phase,retrophin,fda,clearance,clinical,company,tolerability,pharmacokinetics",
            "recuweb_url": "http://en.recuweb.com/pharmacokinetics/businesswire.com/2015/04/retrophin-announces-fda-review-of-ind-for-re-024-and-clearance",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacokinetics&format=RSS&cc=us",
            "source_url": "http://businesswire.com/news/home/20150430006468/en/Retrophin-Announces-FDA-Review-IND-RE-024-Clearance"
        },
        "healio.com/2015/04/rociletinib-azd9291-active-in-egfr-inhibitor-resistant-nsclc": {
            "title": "Rociletinib, AZD9291 active in EGFR inhibitor-resistant NSCLC...",
            "snippet": "Treatment was administered in continuous 21-day cycles. Safety, side-effect profile, pharmacokinetics and preliminary antitumor activity served as the primary study objectives. An efficacy analysis included 63 patients with confirmed T790M status...",
            "date": "2015-04-30",
            "categories": "pharmacokinetics",
            "tags": "patients,efficacy,study,resistant,treatment,continuous,safety,pharmacokinetics",
            "recuweb_url": "http://en.recuweb.com/pharmacokinetics/healio.com/2015/04/rociletinib-azd9291-active-in-egfr-inhibitor-resistant-nsclc",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacokinetics&format=RSS&cc=us",
            "source_url": "http://healio.com/hematology-oncology/lung-cancer/news/online/{402609dc-c1bf-49a7-a6a9-10967011712e}/rociletinib-azd9291-active-in-egfr-inhibitor-resistant-nsclc"
        },
        "empr.com/2015/04/rare-facial-disorder-drug-designated-orphan-status": {
            "title": "Rare Facial Disorder Drug Designated Orphan Drug Status...",
            "snippet": "RELATED: Musculoskeletal Disorders Resource Center Resolaris is currently being studied in a Phase 1b/2, randomized, double-blind, placebo-controlled trial designed to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of...",
            "date": "2015-04-27",
            "categories": "pharmacokinetics",
            "tags": "immunogenicity,trial,evaluate,safety,drug,phase,double,blind,tolerability,pharmacokinetics",
            "recuweb_url": "http://en.recuweb.com/pharmacokinetics/empr.com/2015/04/rare-facial-disorder-drug-designated-orphan-status",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacokinetics&format=RSS&cc=us",
            "source_url": "http://empr.com/rare-facial-disorder-drug-designated-orphan-drug-status/article/411195/"
        },
        "prnewswire.co.uk/2015/04/taxis-pharmaceuticals-demonstrates-clinical-potential-of-txa709-in-combating-antibiotic-resistance": {
            "title": "TAXIS Pharmaceuticals Demonstrates Clinical Potential of TXA709 in Combating Antibiotic Resistance...",
            "snippet": "With its enhanced potency against multidrug-resistant strains, favorable pharmacokinetics, and greater stability, TXA709 clearly stands apart from other antibiotic agents, stated Mr. Mario. TXA709 thus represents a new class of antibiotics, one...",
            "date": "2015-04-27",
            "categories": "pharmacokinetics",
            "tags": "thus,thus-represents,thus-represents-new,represents,represents-new,represents-new-class,class,antibiotics,antibiotic-agents,agents,clearly,clearly-stands,clearly-stands-apart,stands,stands-apart,apart,greater,greater-stability,stability,resistant,resistant-strains,strains,enhanced,enhanced-potency,enhanced-potency-against,potency,potency-against,potency-against-multidrug,against,against-multidrug,multidrug,combating,resistance,taxis,taxis_pharmaceuticals,pharmaceuticals,clinical,txa,favorable,pharmacokinetics,stated,mario",
            "recuweb_url": "http://en.recuweb.com/pharmacokinetics/prnewswire.co.uk/2015/04/taxis-pharmaceuticals-demonstrates-clinical-potential-of-txa709-in-combating-antibiotic-resistance",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacokinetics&format=RSS&cc=us",
            "source_url": "http://prnewswire.co.uk/news-releases/taxis-pharmaceuticals-demonstrates-clinical-potential-of-txa709-in-combating-antibiotic-resistance-501401701.html"
        },
        "news-medical.net/2015/04/taxis-pharmaceuticals-txa709-compound-shows-promise-in-combating-antibiotic-resistance": {
            "title": "TAXIS Pharmaceuticals'TXA709 compound shows promise in combating antibiotic resistance...",
            "snippet": "With its enhanced potency against multidrug-resistant strains, favorable pharmacokinetics, and greater stability, TXA709 clearly stands apart from other antibiotic agents, stated Mr. Mario. TXA709 thus represents a new class of antibiotics, one...",
            "date": "2015-04-27",
            "categories": "pharmacokinetics",
            "tags": "thus,thus-represents,thus-represents-new,represents,represents-new,represents-new-class,class,antibiotics,antibiotic-agents,agents,clearly,clearly-stands,clearly-stands-apart,stands,stands-apart,apart,greater,greater-stability,stability,resistant,resistant-strains,strains,enhanced,enhanced-potency,enhanced-potency-against,potency,potency-against,potency-against-multidrug,against,against-multidrug,multidrug,combating,resistance,taxis,taxis_pharmaceuticals,pharmaceuticals,txa,favorable,pharmacokinetics,stated,mario",
            "recuweb_url": "http://en.recuweb.com/pharmacokinetics/news-medical.net/2015/04/taxis-pharmaceuticals-txa709-compound-shows-promise-in-combating-antibiotic-resistance",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacokinetics&format=RSS&cc=us",
            "source_url": "http://news-medical.net/news/20150427/TAXIS-Pharmaceuticals-TXA709-compound-shows-promise-in-combating-antibiotic-resistance.aspx"
        }
    }
}